DMACHealthcare · BiotechnologyThe 5 Wall Street analysts covering DiaMedica Therapeutics, Inc. hold a median 12-month price target of $13 — +99.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores DiaMedica Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (68): The share price has been relatively steady.
Quality (25): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DMAC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +99.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 14 Nov 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 14 Nov 2025 | Cantor Fitzgerald | Initiates | Overweight | $25 |
| 15 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 July 2025 | Craig-Hallum | Maintains | Buy | — |
| 18 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 July 2025 | Lake Street | Maintains | Buy | — |
| 29 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Oct 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 Aug 2024 | Oppenheimer | Reiterates | Outperform | — |
| 24 Apr 2024 | Craig-Hallum | Assumes | Buy | $8.00 |
| 21 Mar 2024 | Craig-Hallum | Maintains | Buy | — |
| 21 Mar 2024 | Oppenheimer | Reiterates | Outperform | — |
| 22 June 2023 | Oppenheimer | Upgrade | Outperform | — |
| 7 July 2022 | Craig-Hallum | Maintains | Buy | — |
| 7 July 2022 | Lake Street | Maintains | Buy | — |
| 7 July 2022 | Oppenheimer | Downgrade | Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DMAC appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 11% of US stocks
Cheaper than 82% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 12% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own DiaMedica Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research upgraded DiaMedica Therapeutics (DMAC) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects that could see the stock move higher.
Why it matters — A DMAC watcher would care because the rating upgrade signals improving analyst sentiment around the company's earnings outlook.
Seeking Alpha published the transcript of DiaMedica Therapeutics Inc.'s Q2 2026 earnings call. The excerpt provided includes only the headline and source, with no details on financial results or company commentary.
Why it matters — A DMAC watcher would care because earnings call transcripts are a key source of management commentary and financial detail for the quarter, as published by Seeking Alpha.
DiaMedica Therapeutics reported its second-quarter results, highlighting progress on advancing DM199 for early-onset fetal growth restriction, preeclampsia, and acute ischemic stroke. The company also noted a cash runway expected to extend through 2027.
Why it matters — A DMAC watcher would care because the update shows the company is making progress across multiple clinical programs for DM199 while maintaining a cash runway through 2027, reducing near-term dilution risk.
DiaMedica Therapeutics reported its financial results for the second quarter ended June 30, 2026 and provided a business update. Management will host a conference call on August 11, 2026 to discuss the results and business highlights.
Why it matters — This quarterly update provides DMAC investors with the company's latest financial position and progress on its clinical-stage pipeline for preeclampsia, fetal growth restriction, and acute ischemic stroke.
DiaMedica Therapeutics announced that its second quarter 2026 financial results will be released after the market closes on Monday, August 10, 2026. The company will host a live conference call the following morning, Tuesday, August 11, at 8:00 AM Eastern Time, to provide a business update.
Why it matters — DMAC watchers will tune in to the August 11 call for the latest update on the company's clinical-stage programs and its financial position.
The 5 Wall Street analysts covering DiaMedica Therapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $11 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering DiaMedica Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DiaMedica Therapeutics, Inc. 48 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, DiaMedica Therapeutics, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (68 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +99.7% from the last close, and Ticker Nerd's factor model ranks DiaMedica Therapeutics, Inc. 48 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering DiaMedica Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DMAC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $25 over the next 12 months.
DiaMedica Therapeutics, Inc. returned +9.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing innovative therapies for serious vascular diseases driven by restricted blood flow and endothelial dysfunction.
The most recent item we track (Zacks Investment Research, 13 Aug 2026): "All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy". Zacks Investment Research upgraded DiaMedica Therapeutics (DMAC) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects that could see the stock move higher.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing innovative therapies for serious vascular diseases driven by restricted blood flow and endothelial dysfunction. Its lead candidate, DM199, is a recombinant form of the human tissue KLK1 protein, designed to enhance blood flow and vascular health by increasing levels of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor. The company focuses on advancing DM199 for the treatment of preeclampsia, fetal growth restriction, and acute ischemic stroke, with ongoing clinical programs including Phase 2 investigator-sponsored trials and the ReMEDy2 Phase 2/3 trial. DiaMedica Therapeutics Inc. also explores applications in chronic kidney disease. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company engages in clinical development, regulatory interactions, and corporate activities to address unmet needs in these critical therapeutic areas.
CEO Mr. Dietrich John Pauls MBA · 35 employees · United States · https://www.diamedica.com